Novartis Investigative Site

Parma, PR 43126

0 studies enrolling now · 26 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer, Acute Decompensated Heart Failure, Acute Heart Failure, Advanced Non Small Cell Lung Cancer (NSCLC), Asthma, Atherosclerosis, Breast Cancer, Cardiovascular Disease, Chronic Heart Failure, Chronic Kidney Disease (CKD), Chronic Severe Plaque-type Psoriasis, Congestive Heart Failure

Studies at this site

• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects — Stopped early
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis — Completed
• Dose Finding Study for QAW039 in Asthma — Completed
• Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer — Completed
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges — Completed
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification — Stopped early
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation — NO_LONGER_AVAILABLE
• An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations — Stopped early
• Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) — Completed
• A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi — Stopped early
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study — Stopped early
• LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients — Completed
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment — Completed
• Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer — Stopped early
• Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer — Completed
• Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer — Completed
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis — Stopped early
• Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure — Completed